William Burns
Non-Executive Director @ Mesoblast
Basel, Switzerland
William Burns is a startup investor at Mesoblast in Basel. Mr. William M. Burns, also known as Bill, BA serves as the Chief Executive Officer of Roche's Pharmaceutical Division at Roche Carolina Inc. Mr. Burns has extensive experience in biotechnology. He has built a distinguished track record in the pharmaceutical industry over the last 40 years. He served as the Chief Executive Officer ofPharmaceuticals Division of Hoffmann-La Roche Inc. He served as Head of the Pharmaceuticals Division at Hoffmann-La Roche Inc. He served as the Chief Executive Officer of Pharmaceuticals Division of Roche Holding AG from January 2004 to December 31, 2009. Mr. Burns served as Head of Pharmaceuticals Division at Roche Holding AG since 2001. Mr. Burns served as the Head of the Pharmaceuticals Division of Roche Holding AG from 2001 to December 15, 2004. From 1998 to 2001, he served as the Head of Europe and International Business of Roche Pharmaceuticals. From 1991 to 1998, he served as Global Head of Strategic Marketing and Business Development for Roche Pharmaceuticals. Mr. Burns served for Beecham Pharmaceuticals since 1969 as a Management Trainee since 1969. He spent the next 17 years with Beecham in a variety of roles of increasing responsibility, based in the UK and Japan. He served as a Director of Sales & Marketing of Roche UK since 1986 and as its Head of Pharmaceuticals Division since 1988. He served as the Global Head of Strategic Marketing & Business Development of Hoffmann-La Roche Inc., Basel since 1991 and Head of Europe/International since 1998. He was responsible for Global Business Development and Strategic Marketing. His responsibilities also included all international commercial operations. He serves as the Chairman of Masters Pharmaceuticals. Mr. Burns has been the Chairman of the Board at Okairos AG since September 14, 2011. He has been the Deputy Chairman of Biotie Therapies Corp. since March 29, 2012. He has been a Non Executive Director at Shire plc since March 15, 2010. He has been a Director at Biotie Therapies Corp. since February 7, 2011. He serves as a Member of the Supervisory Board at Crucell Sweden AB. He has been a Member of the Supervisory Board at Crucell NV since June 2010. He has been Non-Executive Director of Mesoblast Limited since March 06, 2014. He has been a Director at Chugai Pharmaceutical Co. Ltd., Japan since 2002 and Genentech Inc. since April 2004. He served as a Director of Roche Holding AG since March 2, 2010. He serves as a Director of Vestergaard Frandsen S.A. He served as Chairman of Interpharma, the Swiss research companies' trade association. Mr. Burns received a Bachelor of Arts (Honours Degree) in Business Economics from the University Strathclyde.
Last updated:
For AI agents: llms.txt
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
About Mesoblast
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes, and kidney disease, orthopedicspine conditions, and cardiovascular disorders.
Mesoblast Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Devine
Consultant
|
|||
|
Doreen Morgan
VP Global Regulatory
|
|||
Eric A. Rose
Chief Medical Officer (CMO)
|
|||
Fred Grossman
Chief Medical Officer
|
|||
John Mcmannis
Executive Vice President, Manufacturing
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
How do I contact William Burns?
Public channels for William Burns include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
